By using a composite behavioral and circuit biomarker to identify a subgroup of patients with depression and targeting the α2A receptor with GIR, we demonstrate for the first improvements in neural circuit function, clinical outcomes, cognitive performance, and psychosocial outcomes. Here, GPR83 is linked to major depressive disorder.